Table 3.

Clinical Trials Utilizing PARPi Monotherapy

Treatment	Clinical Trials Identifier	Phase	Status	Patient Population	Eligibility and Exclusion	Primary Endpoints	Secondary Endpoints
Olaparib	NCT02677038	II	Active, Recruiting	-PDAC patients with HRD (BRCAness) -Germline BRCA1/2 excluded	-Stage IV -One line of prior therapy for metastatic disease	Objective response rate	OS PFS CA19-9, Toxicity
Rucaparib	NCT03140670	II	Active, Recruiting	PDAC with Germline or Somatic BRCA1/2, PALB2 mutations	-Stage III or IV -Patients currently on platinum therapy for advanced PDAC and not have progressed	Number of adverse events	N/A
Niraparib	NCT03601923	II	Active, Recruiting	PDAC with Germline or Somatic BRCA1/2, PALB2, CHEK2, or ATM mutations	-Stage III & IV -One line of prior therapy for metastatic disease	PFS	Overall response rate OS Safety and tolerability

Abbreviations: CA 19–9, Cancer antigen 19–9; PDAC, Pancreas Ductal Adenocarcinoma; PFS, Progression Free Survival; OS, Overall Survival.